These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10382110)

  • 1. Analysis of chromameter results obtained from corticosteroid-induced skin blanching assay: comparison of visual and chromameter data.
    Schwarb FP; Smith EW; Haigh JM; Surber C
    Eur J Pharm Biopharm; 1999 May; 47(3):261-7. PubMed ID: 10382110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the proposed FDA pilot dose-response methodology for topical corticosteroid bioequivalence testing.
    Demana PH; Smith EW; Walker RB; Haigh JM; Kanfer I
    Pharm Res; 1997 Mar; 14(3):303-8. PubMed ID: 9098871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of chromameter results obtained from corticosteroid-induced skin blanching. I: Manipulation of data.
    Smith EW; Haigh JM; Walker RB
    Pharm Res; 1998 Feb; 15(2):280-5. PubMed ID: 9523316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence assessment of topical clobetasol propionate products using visual and chromametric assessment of skin blanching.
    Au WL; Skinner M; Kanfer I
    J Pharm Pharm Sci; 2008; 11(1):160-6. PubMed ID: 18445371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between in vivo skin blanching and in vitro release rate for betamethasone valerate creams.
    Shah VP; Elkins J; Skelly JP
    J Pharm Sci; 1992 Jan; 81(1):104-6. PubMed ID: 1619561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potency ranking of two new topical corticosteroid creams containing 0.1% desonide or 0.05% halometasone utilising the human skin blanching assay.
    Meyer E; Smith EW; Haigh JM; Kanfer I
    Arzneimittelforschung; 1988 Dec; 38(12):1840-3. PubMed ID: 3245859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of serial dilution of betamethasone-17-valerate on blanching potential and chemical stability.
    Ryatt KS; Cotterill JA; Mehta A
    J Clin Hosp Pharm; 1983 Jun; 8(2):143-5. PubMed ID: 6875011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical 0.050% betamethasone dipropionate. Pharmacokinetic and pharmacodynamic dose-response studies in humans.
    Pershing LK; Lambert L; Wright ED; Shah VP; Williams RL
    Arch Dermatol; 1994 Jun; 130(6):740-7. PubMed ID: 8002644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of measuring the bioavailability of topical betamethasone dipropionate in commercial formulations using drug content in skin and a skin blanching bioassay.
    Pershing LK; Silver BS; Krueger GG; Shah VP; Skelley JP
    Pharm Res; 1992 Jan; 9(1):45-51. PubMed ID: 1589409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of some variables affecting the blanching activity of betamethasone 17-valerate cream.
    Magnus AD; Haigh JM; Kanfer I
    Dermatologica; 1980; 160(5):321-7. PubMed ID: 7364141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the bioactivity of mometasone furoate 0.1% fatty cream, betamethasone dipropionate 0.05% cream and betamethasone valerate 0.1% cream in humans. Inhibition of UV-B-induced inflammation monitored by laser Doppler blood flowmetry.
    Bjerring P
    Skin Pharmacol; 1993; 6(3):187-92. PubMed ID: 8274288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of skin-colour changes induced by topical corticosteroid preparations using the Minolta Chroma Meter.
    Queille-Roussel C; Poncet M; Schaefer H
    Br J Dermatol; 1991 Mar; 124(3):264-70. PubMed ID: 2018732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of corticosteroid-induced skin vasoconstriction: visual ranking, chromameter measurement or digital imaging analysis.
    Smith EW; Haigh JM; Surber C
    Dermatology; 2002; 205(1):3-10. PubMed ID: 12145427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity of different areas of the flexor aspect of the human forearm to corticosteroid-induced skin blanching.
    Meyer E; Smith EW; Haigh JM
    Br J Dermatol; 1992 Oct; 127(4):379-81. PubMed ID: 1419758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Onset of the vasoconstrictor effect of diflucortolone valerate, betamethasone valerate, and fluocinolone acetonide ointments applied for varying periods under occlusive dressings.
    Szadurski J; Renz F; Gasser D
    Dermatologica; 1976; 153(4):236-42. PubMed ID: 1017533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The stability and blanching efficacy of betamethasone-17-valerate in emulsifying ointment.
    Ryatt KS; Feather JW; Mehta A; Dawson JB; Cotterill JA; Swallow R
    Br J Dermatol; 1982 Jul; 107(1):71-6. PubMed ID: 7104209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blanching activities of betamethasone formulations. The effect of dosage form on topical drug availability.
    Smith EW; Meyer E; Haigh JM
    Arzneimittelforschung; 1990 May; 40(5):618-21. PubMed ID: 2383308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of topical application of clobetasol 17-propionate from various cream bases.
    Fang JY; Shen KL; Huang YB; Wu PC; Tsai YH
    Drug Dev Ind Pharm; 1999 Jan; 25(1):7-14. PubMed ID: 10028413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids.
    Schäfer-Korting M; Korting HC; Kerscher MJ; Lenhard S
    Clin Pharmacol Ther; 1993 Oct; 54(4):448-56. PubMed ID: 8222488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative blanching activities of proprietary diflucortolone valerate topical preparations.
    Coleman GL; Kanfer I; Haigh JM
    Dermatologica; 1978; 156(4):224-30. PubMed ID: 342295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.